Molecular Determinants of Sotorasib Efficacy in Patients with Advanced KRASG12C-mutated NSCLC By Ogkologos - June 6, 2025 726 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from integrated analyses of sotorasib clinical efficacy biomarkers in the CodeBreaK 100 and CodeBreaK 200 studies Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Larger NGS Gene Panel Linked to More Clinical Utility October 16, 2020 Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation... July 9, 2025 Colon capsule endoscopy – reshaping bowel cancer diagnosis April 14, 2021 Some Brain Cells May Help to Fuel Cancer Metastasis November 21, 2019 Load more HOT NEWS Identifying Safer Ways to Look for Recurrence After Testicular Cancer Surgery Biomarker Data from the KAITLIN Study in High-Risk Early Breast Cancer Savolitinib Plus Osimertinib Show a High Response in EGFR-mutated NSCLC Progressed... Paclitaxel and Carboplatin Not Inferior When Compared with Paclitaxel and Ifosfamide...
